Open Orphan (LON:ORPH) has rapidly restructured and integrated its Venn and hVIVO subsidiaries, and is delivering on its growth strategy by maximising its specialist capabilities and is converting a pipeline with an estimated value of over £100mln, to deliver long-term, profitable contracts.

This was highlighted by a recent win with a top-three global pharma company to deliver a respiratory syncytial virus (RSV) human challenge study clinical trial, reinforcing its world-leading position in the space. ORPH is also driving forward its strategy via expanding hVIVO lab services to third-parties and has signed a series of new contracts with antiviral, vaccine and respiratory therapeutic developers, including a COVID-19 vaccine testing contract with Codagenix.